AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04005716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin / Cisplatin, Etoposide
Description: Placebo Q3W in combination with chemotherapy consisting of etoposide (100 mg/m² IV Days 1-3 of each 21-day cycle) and platinum (cisplatin 75 mg/m² IV Q3W or carboplatin AUC 5 IV Q3W) for 4 cycles. Then maintenance consists of Placebo Q3W and will continue until disease progression, loss of clinical benefit, unacceptable toxicity, or withdrawal of informed consent.
Study NCT03437941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT125281
Description: CORT125281 is supplied as capsules for oral dosing
Study NCT03437941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide (Xtandi)
Description: Enzalutamide will be taken orally
Study NCT03437941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules to match the appearance of the CORT125281
Study NCT02367352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib tablets
Study NCT02367352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel intravenous solution
Study NCT01006525 — intervention group
Intervention type: DRUG
Intervention: zolpidem
Description: placebo or zolpidem (10mg)daily for one year
Study NCT04658563 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Density Exercise Training Program - Yoga
Description: A total of 8 weeks will be applied in our study, each session of the high-density yoga program will be started with 10 minute pranayama (breath) exercises as it is in classical yoga as a preliminary preparation for the participation of individuals; the program will be completed by applying 10-20 minutes warming-stretching movements, 40 minutes surya namaskar (SN) sets, 20-30 minutes dynamic yoga asanas and 10 minutes savasana. Participants will be encouraged to study the perceived difficulty levels between 14 and 17 using the Borg scale during the sessions
Study NCT04142099 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: skin to skin contact 60 min group
Description: Newborns are exposed to maternal and child skin within five minutes of birth for 60 min.
Study NCT03349489 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dexcom G4 Platinum
Description: The Dexcom G4 Platinum will be used to measure continuous glucose levels.
Study NCT03349489 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Participant's usual fast-acting insulin analog will be used.
Study NCT03349489 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin pump
Description: Participant's insulin pump will be used to infuse insulin.
Study NCT04142099 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: skin to skin contact 20min group
Description: Newborns are exposed to maternal and child skin within five minutes of birth for 20 min.
Study NCT04592497 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AF ablation
Description: Prospective, single-center, non-randomized, open label, two arm study. After informed consent, 60 consecutive subjects who are scheduled to undergo AF ablation will be enrolled in the study in two equally sized groups of 30 subjects each. One group will undergo the procedure with assistance THERMOCOOL SMARTTOUCH SF-5D QDOT system and the other with the standard Thermocool Smartouch SF system. Data will be collected from all subjects during the ablation procedure and post procedure for a period of 12 months. Data will be anonymized by removing patient protected health information, only initials will be used.
Study NCT01066663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrimethamine
Description: Taken orally once a day
Study NCT01687283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate inhalation solution
Description: 1 mg BID inhalation for 12 weeks with one possible chance to change to 0.5 mg BID
Study NCT01687283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide suspension
Description: 2 mg BID inhalation for 12 weeks with one possible chance to change to 1 mg BID
Study NCT04361097 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplant
Description: Both groups will receive frozen capsules to be ingested orally (constituted of TMF or placebo according to the randomization) with a frequency of 15 capsules every 12hrs for 4 doses on days 1, 10 and 30 of the study. Each capsule should be ingested in a period no longer than 1 hour.
Study NCT04361097 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Both groups will receive frozen capsules to be ingested orally (constituted of TMF or placebo according to the randomization) with a frequency of 15 capsules every 12hrs for 4 doses on days 1, 10 and 30 of the study. Each capsule should be ingested in a period no longer than 1 hour.
Study NCT02824562 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intervention
Description: The intervention group will receive treatment as usual plus a chronic pain self-management program which includes six one-on-one sessions facilitated by a trained interventionist and six group sessions facilitated by a trained interventionist and a peer. A peer is an HIV-infected patient living with chronic pain, who has completed all ten of the one-on-one sessions offered, received training to co-facilitate the six group sessions with the interventionist, and is successfully self-managing his/her chronic pain.
Study NCT02824562 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: The control group will receive treatment as usual. The treatment as usual or control group refers to the standard of care that patients receive for their chronic pain. This standard of care allows patients to discuss chronic pain with their providers at their discretion. Although highly variable, providers can recommend and prescribe pharmacologic (e.g., opioid and other pain medication), non-pharmacologic (e.g., physical therapy, referral to psychology) approaches for pain. This study will not interfere in any way with usual care. No additional treatment will be provided to participants allocated to the control group.
Study NCT02360748 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant based high protein food items
Description: Patients will add high protein plant based food items to their diet
Study NCT04592497 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AF ablation
Description: Prospective, single-center, non-randomized, open label, two arm study. After informed consent, 60 consecutive subjects who are scheduled to undergo AF ablation will be enrolled in the study in two equally sized groups of 30 subjects each. One group will undergo the procedure with assistance THERMOCOOL SMARTTOUCH SF-5D QDOT system and the other with the standard Thermocool Smartouch SF system. Data will be collected from all subjects during the ablation procedure and post procedure for a period of 12 months. Data will be anonymized by removing patient protected health information, only initials will be used.
Study NCT04340765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-fluorocholine
Description: Dual phase 18F-fluorocholine PET/CT
Study NCT01520337 — intervention group
Intervention type: DEVICE
Intervention: oral tablet dye for detection of polyps during colonoscopy
Description: oral tablet dye for improved detection of
Study NCT02904785 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Waves
Study NCT02904785 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Extracorporeal Shock Waves
Study NCT02904785 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activities
Description: Patients receive instructions for physical activities for strengthening of femoral quadriceps and stretching of hamstring muscles.
Study NCT02904785 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Physical activities
Description: Patients receive instructions for physical activities for strengthening of femoral quadriceps and stretching of hamstring muscles.
Study NCT02895360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAL101553
Description: BAL101553 48-hour infusion on day 1, 8, and 15 of each 28-day cycle; oral capsule daily for one week during Cycle 2 (study days 15-21)
Study NCT02895360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAL101553 at MTD
Description: BAL101553 48-hour infusion on day 1, 8, and 15 of each 28-day cycle; treatment with maximum tolerated dose (MTD)
Study NCT03922152 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short course radiotherapy
Description: An accelerated hypo-fractionation 2D-radiotherapy is delivered for palliation in patients with advanced esophageal cancer.
Study NCT00131963 — intervention group
Intervention type: DRUG
Intervention: cyclophosphamide
Description: Given IV
Study NCT00131963 — intervention group
Intervention type: DRUG
Intervention: doxorubicin
Description: Given IV
Study NCT00131963 — intervention group
Intervention type: DRUG
Intervention: paclitaxel
Description: Given IV
Study NCT03502577 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCMA-specific CAR-expressing T Lymphocytes
Description: Receive CAR T infusion
Study NCT03502577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT03502577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT03502577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gamma-Secretase Inhibitor LY3039478
Description: Given PO
Study NCT03502577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03502577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Study
Description: Correlative studies
Study NCT01765738 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PICC (Cook, Bard)
Description: Comparison of antibiotic coated PICC vs. non-coated PICC
Study NCT01114490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anacetrapib
Description: single dose administration of anacetrapib (MK0859) 100 mg oral tablet
Study NCT02543099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: policosanol
Description: Patients will receive policosanol 20mg Qd
Study NCT02543099 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients will receive placebo 20mg Qd;
Study NCT02325362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miglustat ; placebo
Description: For this 2 x 2 (2 periods /2 treatments) crossover design each patient will receive Miglustat during the first period (2 weeks), following by a wash out period(14 days (up to 4 weeks)), then Placebo during the second period (2 weeks). 30 days follow-up will be carried out after end-of-treatment of the second period.
Study NCT02325362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo ; Miglustat
Description: For this 2 x 2 (2 periods /2 treatments) crossover design each patient will receive Placebo during the first period (2 weeks), following by wash out period (14 days (up to 4 weeks)), then Miglustat during the second period (2 weeks). 30 days follow-up will be carried out after end of treatment of the second period.
Study NCT04155034 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04155034 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04155034 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Prophylactic Cranial Irradiation
Description: Undergo PCI
Study NCT03219177 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient education regarding indications for opioid use and side effects of opioid use after hand surgery
Description: Patients in the active education group will be given information pre-operatively on the current opioid epidemic, alternative pain management strategies that should be tried before proceeding to prescription opioid use, appropriate indications for opioid use, and side effects of opioids.This information will be reinforced by the research coordinator and nursing staff in the post-anesthesia care unit.
Study NCT03219177 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care post-operative counseling
Description: Patients will receive standard of care post-operative counseling. They will not be given pre or post-operative opioid education.
Study NCT00886353 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: APN01
Description: APN01, a physiological formulation of recombinant human Angiotensin Converting Enzyme 2 administrated i.v.
Study NCT00886353 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Physiological saline administrated i.v.
Study NCT03178344 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XCSITE100 Stimulator tACS
Description: Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied.
Study NCT03178344 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XCSITE100 Stimulator Sham
Description: The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session.
Study NCT04468230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Transdermal Patch
Description: Nicotine Treatment Condition
Study NCT03017937 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Q-collar
Description: capture ultrasound images at each pressure point
Study NCT03540745 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TES Treatment
Description: Device: Nexalin Based Trans-Cranial Electrical Stimulation The Nexalin device, FDA clearance (501K=K024377, Classification: Stimulator, Cranial Electrotherapy: CFR 882. 5800: U.S. Patent #6904322B2), produces a square waveform that provides trans-cranial electrical stimulation to the brain delivered at a frequency of 77.5 Hz at 0 to 4 mA peak current. Other Name: TES
Study NCT03540745 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TES-SHAM Treatment
Description: Device: Nexalin Based Trans-Cranial Electrical Stimulation The Nexalin device, FDA clearance (501K=K024377, Classification: Stimulator, Cranial Electrotherapy: CFR 882. 5800: U.S. Patent #6904322B2), produces a square waveform that provides trans-cranial electrical stimulation to the brain delivered at a frequency of 77.5 Hz at 0 to 4 mA peak current. Other Name: TES
Study NCT04225741 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training group
Description: The single-session training lasted for approximately 40-45 minutes and was conducted in the training room of Sıtmapınarı family health center, as a suitable environment. The health belief model predicts the determinants of preventive health behaviors and explains inadequate participation in disease prevention and screening programs. Furthermore, this model not only explains behavior regarding screening, but also evaluates the cognitive factors that facilitate health-promoting behaviors.
Study NCT03313141 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Volitional and non volitional respiratory tasks
Study NCT00531726 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBS of Cg25
Study NCT00531726 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: DBS of Cg25
Study NCT01855347 — intervention group
Intervention type: DEVICE
Intervention: Near Infrared Spectroscopy
Description: NIRS Monitoring with four channels regional areas of the preterm infant, such as: Submandibular, Periumbilical, Abdominal (Spleen region) and infant thigh.
Study NCT04700059 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual perinatal home visiting
Description: 10 perinatal home visits
Study NCT00508495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol (acetaminophen)
Description: Four 100 mL, 15 min IV infusions at six hour intervals
Study NCT00508495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol 1% solution
Description: Four 100 mL, 15 min IV infusions at six hour intervals
Study NCT00508495 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride solution
Description: Four 100 mL, 15 min IV infusions at six hour intervals
Study NCT04883060 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: midline localizer
Description: a midline localizer device with a laser pointer is used to localize where the midline is likely to be located on the patient head prior to the surgery.
Study NCT03005990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training group
Description: The conditioning period (24 weeks) of the exercise intervention was under the supervision of an exercise physiologist. The conditioning protocol included aerobic exercise sessions 3 times per week with 70-85% of maximal heart rate(max HR) for 30 mins and resistance sessions 3 times per week with an intensity of 80% of one-repetition maximum(1RM), 3 sets of 8 repetitions maximum. Each participant will measured the borg rating of perceived exertion scale and heart rate monitor during exercise. Exercise sessions were conducted in the afternoon (3-5 PM).
Study NCT01951768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Garamycin Sponge (Gentamicin-Collagen sponge)
Description: Gentamicin Collagen Sponge: 5 × 5 cm in size containing Type I bovine collagen and 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)
Study NCT01951768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic Antibiotic
Description: Antibiotics options per protocol:~Levofloxacin PO 750 mg q.24h or 500 mg q.12h Levofloxacin IV 750 mg q.24h or 500 mg q.12h Amoxicillin/clavulanate PO 500/125 mg q.12h. or q.8h Amoxicillin/clavulanate IV 1000/200 mg q.12h or q.8h Clindamycin PO 300 mg or 450 mg q.6h Clindamycin IV 600 mg q.8h or q.6h Linezolid PO 600 mg q.12h Linezolid IV 600 mg q.12h Metronidazole PO 400 mg or 500 mg q.8h or 500 mg q.6h Metronidazole IV 500 mg q.8h or q.6h Aztreonam IV 1 g or 2 g q.12h or q.8h Piperacillin/tazobactam IV 3000/375 mg q.6h or 4000/500 mg q.8h
Study NCT01076790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine infusion 1 mcg/kg in 10 minutes; thereafter 0.7 mcg/kg/h until 30 minutes has elapsed from skin incision.
Study NCT01076790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Saline infusion 1 mcg/kg in 10 minutes; thereafter 0.7 mcg/kg/h until 30 minutes has elapsed from skin incision.
Study NCT02614612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib (200 mg)
Study NCT02614612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib (300 mg)
Study NCT02614612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone or methylprednisolone (corticosteroids)
Description: All subjects will receive prednisone 2.5 mg/kg per day PO (or methylprednisolone 2 mg/kg IV daily) on Days 1 through 5. Subjects will be tapered as tolerated beginning on Day 6 to no less than 0.25 mg/kg per day PO (or methylprednisolone 0.2 mg/kg per day) by Day 28. After Day 28, corticosteroids should be tapered according to institutional guidelines to attain ≤ prednisone 0.2 mg/kg per day (or ≤ methylprednisolone 0.16 mg/kg per day) by Day 56.
Study NCT00301483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemoglobin-based oxygen carrier-201 (HBOC 201)
Description: HBOC-201 is an investigational solution of sterile, ultrapurified, glutaraldehyde polymerized, modified bovine hemoglobin (Hb) in a balanced electrolyte solution. HBOC-201 has an Hb concentration of 12-14g/dL. HBOC-201 is an isosmotic solution that is stable for at least 36 months at 2-30ºC. It requires no reconstitution and can be administered directly into a peripheral or central vein. Blood typing is not required because all other cellular components, including the RBC membranes that carry the blood group antigens, have been removed.
Study NCT00301483 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard Therapy
Study NCT00996502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Phase I:~* Cohort 1: 55mg/m2 of Docetaxel on Day 1 of the cycle~* Cohort 2: 65mg/m2 of Docetaxel on Day 1 of the cycle~* Cohort 3: 75mg/m2 of Docetaxel on Day 1 of the cycle
Study NCT00996502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15mg/kg of Bevacizumab every 3 weeks
Study NCT00996502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 200 mg of Erlotinib PO daily days 2-16
Study NCT00996502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg of Prednisone PO bid
Study NCT00302159 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study NCT00302159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Orally 75mg/m\^2 first day of radiation until completion. Restart 4 weeks post radiation.
Study NCT00302159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: Orally 25mg/kg/day twice a day concurrently with radiation therapy and temozolomide.